Drug Trial Radar · NCT04159415
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 7, 2020
Primary completion
Jan 5, 2022
Study completion Sep 24, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL). The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.
Conditions
- Generalized Lipodystrophy
Interventions
PlaceboDrug
Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
Low-Dose REGN4461Drug
IV infusion loading dose or SC injection QW.
High-dose REGN4461Drug
IV infusion loading dose or SC injection QW.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8Time frame: Baseline, Week 8
- Absolute Change From Baseline in Fasting Glucose at Week 8Time frame: Baseline, Week 8
- Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8Time frame: Baseline, Week 8
- Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8Time frame: Baseline, Week 8
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Bethesda, Maryland
Regeneron Research Site
Ann Arbor, Michigan
Regeneron Research Site
Dallas, Texas
Regeneron Research Site
Piura, Peru
Regeneron Research Site
Moscow, Russia
Regeneron Research Site
Ankara, Turkey (Türkiye)
Regeneron Research Site
Diyarbakır, Turkey (Türkiye)
Regeneron Research Site
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.